Ionis Pharmaceuticals CEO Brett Monia Buys Shares

Brett Monia, the CEO of Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS), made a notable purchase of company stock. On June 24, 2026, Monia acquired 14,565 shares at an average price of $32.6 per share, amounting to a total investment of $474,819. This transaction was not part of any pre-arranged trading plan.

Other Institutional Activity in Ionis Pharmaceuticals

FMR LLC increased its holdings in Ionis Pharmaceuticals by 484,536 shares, bringing its total to 24,556,637 shares valued at approximately $1.84 billion. CAPITAL WORLD INVESTORS added 3,225,070 shares, raising its stake by 18% to 21,186,369 shares worth about $1.59 billion. BLACKROCK, INC. trimmed its position by 205,387 shares, now holding 10,442,476 shares valued at $784 million. Meanwhile, VANGUARD PORTFOLIO MANAGEMENT LLC and VANGUARD CAPITAL MANAGEMENT LLC both opened new positions, with holdings of 7,808,902 and 7,118,330 shares respectively.

Ionis Pharmaceuticals, Inc. Stock Up 33.0%

Shares of Ionis Pharmaceuticals traded near $78.34 on Saturday. The company, which operates under the NasdaqGS ticker IONS, boasts a market capitalization of about $12.95 billion. While the company isn't currently profitable, it has a beta of 0.37, indicating less volatility compared to the market. The stock's 52-week range spans from $39.37 to $86.74, with a 50-day moving average of $74.96 and a 200-day moving average of $75.32. Ionis has a solid current ratio of 4.10 and a quick ratio of 2.86, though it carries a high debt-to-equity ratio of 531.05.

Recent Earnings

In its latest financial report, Ionis Pharmaceuticals posted revenue of $1.06 billion, showing a modest growth of 0.87%. Despite this, the company reported a net margin of -30.9% and a return on equity of -67.6%. The next earnings report is anticipated on April 29, 2026.

Insider Buying and Selling at Ionis Pharmaceuticals, Inc.

In addition to Brett Monia's purchase, other transactions occurred around the same period. On June 26, Monia engaged in a planned sale of 50,000 shares at $80.59. Eric Swayze, Executive Vice President of Research, sold 10,602 shares at $79.18 on June 25 under a planned transaction.

Analysts Set New Price Targets

On June 25, 2026, Goldman Sachs maintained a 'hold' rating with a price target of $75. Leerink Partners and HC Wainwright & Co. both reaffirmed their 'buy' ratings, with price targets of $129 and $130, respectively. The consensus among 23 analysts is a 'buy' rating, with a mean target price of $105.91.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California. It focuses on developing RNA-targeted medicines. The company offers treatments for various conditions, including spinal muscular atrophy and hereditary transthyretin amyloidosis. Ionis collaborates with major pharmaceutical companies like Biogen, GSK, and Roche to advance its drug pipeline.

Bottom Line

Brett Monia's stock purchase at Ionis Pharmaceuticals is a significant insider move. Investors often watch such transactions for potential insights into company prospects. However, it's important to remember that these filings reflect past actions and may not indicate current positions. Ionis remains a notable player in the biotechnology sector, with ongoing partnerships and a robust pipeline.